Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Queen Savang Vadhana Memorial Hospital, Thailand
- Target Recruit Count
- 70
- Registration Number
- NCT05940233
- Locations
- 🇹🇭
Sutinee Srimahachota, Bangkok, Yannawa, Thailand
Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT05918718
- Locations
- 🇮🇷
Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of
A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1180
- Registration Number
- NCT05909397
- Locations
- 🇺🇸
Lakeland Regional Cancer Center, Lakeland, Florida, United States
🇺🇸Radiology and Imaging Specialists, Lakeland, Florida, United States
🇺🇸Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 766
- Registration Number
- NCT05891093
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 100
- Registration Number
- NCT05872204
- Locations
- 🇫🇷
Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, Île-de-France, France
🇳🇱Erasmus Medical Center Rotterdam, Rotterdam, South Holland, Netherlands
🇫🇷Centre Leon Berard, Lyon, Métropole De Lyon, France
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT05867251
- Locations
- 🇺🇸
NEXT Virginia, Fairfax, Virginia, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania, United States
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3100
- Registration Number
- NCT05827081
- Locations
- 🇦🇺
Novartis Investigative Site, Gateshead, New South Wales, Australia
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Yongsheng Wang
- Target Recruit Count
- 100
- Registration Number
- NCT05809024
- Locations
- 🇨🇳
Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4300
- Registration Number
- NCT05774951
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.